Seattle, Washington, USA · also Partner clinics across 8 states
TPE / plasma exchange69ARK score
3 documented red flags
Publishes biological-age claims ('2.61 years younger') that outrun the evidence — no human study has shown that lowering a clock reading extends life or prevents disease.
TPE's own best-designed trial (AMBAR) missed one of two co-primary endpoints.
Per-session price tier with a biomarker-only result behind it.
Published on every entry, including the top-ranked ones. A clinic with no red flags listed has not been proved clean — it has not had one found in this research pass.
Published price
$8,000 – $10,000 / sessionVerified price
per session
Reported span across sources is $5,000–$15,000.
ARK never bills treatment and takes no share of what a clinic charges you — you pay the clinic or vendor directly. Prices shown are their own published prices, labelled with how they were verified.
What they do
Therapeutic plasma exchange with albumin replacement, IVIG add-on available. Delivered as a network layered onto existing partner clinics; superbill provided.
The evidence behind the primary service
TPE with albumin (therapeutic plasma exchange) — grade D, carried unchanged from the ARK Protocol Library. A clinic's score cannot exceed 20 of 100 on service evidence, so no clinic can rank well on an unproven therapy.
AMBAR — the best-designed TPE trial, run in Alzheimer's patients — missed one of its two co-primary endpoints. Its 18-procedure protocol is also not what anyone sells.
The longevity result is a biomarker-only outcome from roughly 11 patients per arm, in a study funded by the seller.
Score breakdown
Price transparency25/25
Medical leadership15/25
Regulatory standing20/20
Evidence behind the primary service8/20
Disclosure & clean record1/10
Price transparency: Price published and independently sourced.
Medical leadership: Physician-run protocols across partner sites; per-site oversight varies and no single named medical director was captured.
Regulatory standing: US clinics; apheresis performed on FDA-cleared devices, off-label for this indication.
Evidence behind the primary service: ARK Protocol Library grade D, carried unchanged. Capped at 20 of 100 so no clinic can rank on an unproven therapy.
Disclosure & clean record: 3 documented red flags, published on this card.
Verification status
Medical leadership: Physician-run protocols across partner sites; per-site oversight varies and no single named medical director was captured.
Regulatory: US clinics; apheresis performed on FDA-cleared devices, off-label for this indication.
ARK Verified: No. No clinic in this directory has passed the registry check and the human call. There is no gold star anywhere in this build.
Accreditation (JCI etc.): Not captured for this entry in this research pass. Absence is scored as absence, never as good.
Outcomes / PROMs: None published. No clinic in the directory publishes complication rates.
Shortlisted as a partner candidate: its entire model is layering onto existing clinics, which is the same shape as ARK's delivery-not-molecules position. The bio-age marketing would need to be firewalled from any ARK surface.